---
figid: PMC4250230__nihms640682f3
figlink: /pmc/articles/PMC4250230/figure/F3/
number: F3
caption: Resistance to BRAF inhibitors in metastatic colorectal and thyroid cancers
  is mediated by loss of a feedback loop (EGF→EGFR signaling in colorectal cancers
  or NRG1→HER2 and HER3 signaling in papillary thyroid cancers) whereby the MAP kinase
  pathway activity inhibits mitogen dependent signaling (highlighted in blue). The
  negative feedback loop is disrupted when treated with a RAF inhibitor and proliferation
  is restored through RTK, RAS and PI3K signaling (highlighted in red).
pmcid: PMC4250230
papertitle: 'Targeting RAF kinases for cancer therapy: BRAF mutated melanoma and beyond.'
reftext: Matthew Holderfield, et al. Nat Rev Cancer. ;14(7):455-467.
pmc_ranked_result_index: '11321'
pathway_score: 0.9668518
filename: nihms640682f3.jpg
figtitle: 'Targeting RAF kinases for cancer therapy: BRAF mutated melanoma and beyond'
year: ''
organisms:
- Homo sapiens
ndex: d8d5b9a9-de95-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4250230__nihms640682f3.html
  '@type': Dataset
  description: Resistance to BRAF inhibitors in metastatic colorectal and thyroid
    cancers is mediated by loss of a feedback loop (EGF→EGFR signaling in colorectal
    cancers or NRG1→HER2 and HER3 signaling in papillary thyroid cancers) whereby
    the MAP kinase pathway activity inhibits mitogen dependent signaling (highlighted
    in blue). The negative feedback loop is disrupted when treated with a RAF inhibitor
    and proliferation is restored through RTK, RAS and PI3K signaling (highlighted
    in red).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - HRAS
  - MAPK1
  - BRAF
  - NRAS
  - PI3
  - ARAF
  - MAP2K1
  - MAP2K2
  - MAPK3
  - ERBB2
  - RAF1
  - KRAS
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: (EGFR,
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3'
  symbol: PI3
  source: hgnc_symbol
  hgnc_symbol: PI3
  entrez: '5266'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: HER2/3)
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4250230__F3
redirect_from: /figures/PMC4250230__F3
figtype: Figure
---
